Does normal substantia nigra echogenicity make a difference in Parkinson’s disease diagnosis? A real clinical practice follow-up study
Araceli Alonso‐Cánovas(Universidad de Alcalá), Juan Carlos Martínez‐Castrillo(Hospital Universitario Ramón y Cajal), Javier Buisán(Instituto Cajal), Íñigo Corral(Hospital Universitario Ramón y Cajal), Rafael Toledano(Hospital Ruber Internacional), Lucienne Costa‐Frossard(Universidad de Alcalá), María Consuelo Matute-Lozano(Instituto Cajal), José Luis López-Sendón(Hospital Universitario Ramón y Cajal), Guillermo García‐Ribas(Instituto Ramón y Cajal de Investigación Sanitaria), Alicia de Felipe(Universidad de Alcalá), Beatriz Zarza Sanz(Instituto Ramón y Cajal de Investigación Sanitaria), Jaime Masjuán(Universidad de Alcalá)
Cited by 8
Related Papers
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
|European Journal of Neurology|2020|385
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
|The Lancet|2012|280
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS
|Journal of Clinical Investigation|2005|257